The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and I actually worked uh with Bristol my squib and then uh uh astroica and that eventually led to the uh dly floen coming to the market but what we showed and this is human bio which was the first sglt2 inhibitor that's correct yes brand name on that one uh fora for right yeah and so kega floen was NE igly flows in uh yeah then canag Flows In ugly flows and we have a bunch of them and they all B they're all very good basically do the same thing
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.